Directed new share issue in Camurus AB (SE) — SEK 300 million

Carnegie acted as joint global co-cordinator in the directed new share issue of 3,660,000 new shares at a subscription price of SEK 82 per share. Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. December 2019.